Insulet

Insulet

Health Care Equipment & Supplies
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

$10.2B

Market Cap • 11/6/2026

2000

(26 years)

Founded

2007

(19 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

S&P500 Participant

Index Composite • 2026

Valuation

P/B

6,4

P/S

3,2

P/EBITDA

14,7

P/OCF

20

P/FCF

39,1

P/E

23,9

BVPS

22,8

EPS

6,1

Market Cap

Market Cap

10,2B

EV

10,5B

EV/Revenue

3,3

EV/EBITDA

15,2

EV/EBIT

17,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

2,9%

Total Yield

2,9%

Payout

0%

Retained Earnings

614,5M

Profitability

Gross Margin

71,9%

EBITDA Margin

21,7%

EBIT Margin

18,4%

Net Margin

13,4%

D&A/EBITDA

0%

R&D/Revenue

11,3%

Capex/Revenue

7,8%

Capex/D&A

236%

Capex/OCF

48,9%

SBC/OCF

16,1%

% PPE

26,9%

% Goodwill

1,5%

ROE

28,9%

ROIC

24,6%

Growth

CAGR Revenue 5Y

25,7%

CAGR Op. Income 5Y

53,5%

Leverage

N.D./EBITDA

0,5

Debt/Equity

0%

Current Ratio

2,5

Quick Ratio

1,6

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium